Clinical Trial Update: A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic similarity study comparing AVT32-DRL_PB with Keytruda in participants with fully resected melanoma; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• AVT32-DRL_PB
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Alvotech Swiss AG | Conditions: Melanoma | Phase 1 | Status: NOT_YET_RECRUITING